Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for CervoMed (CRVO) over the last 10 years, with Q3 2025 value amounting to $9.3 million.

  • CervoMed's Shares Outstanding (Weighted Average) rose 631.93% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 631.93%. This contributed to the annual value of $8.1 million for FY2024, which is 20334.06% up from last year.
  • As of Q3 2025, CervoMed's Shares Outstanding (Weighted Average) stood at $9.3 million, which was up 631.93% from $9.0 million recorded in Q2 2025.
  • In the past 5 years, CervoMed's Shares Outstanding (Weighted Average) registered a high of $9.3 million during Q3 2025, and its lowest value of $518140.0 during Q4 2022.
  • For the 4-year period, CervoMed's Shares Outstanding (Weighted Average) averaged around $4.9 million, with its median value being $4.4 million (2023).
  • As far as peak fluctuations go, CervoMed's Shares Outstanding (Weighted Average) plummeted by 7458.51% in 2023, and later soared by 157961.63% in 2024.
  • CervoMed's Shares Outstanding (Weighted Average) (Quarter) stood at $518140.0 in 2022, then skyrocketed by 413.65% to $2.7 million in 2023, then skyrocketed by 203.34% to $8.1 million in 2024, then grew by 14.61% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q3 2025, $9.0 million for Q2 2025, and $8.7 million during Q1 2025.